Fig. 1: Anti-SARS-CoV-2 RBD total Ig responses in whole OCTAVE cohort at post-V2 timepoint.

a, Proportion of group 1 and group 2 non (<0.8 AU ml⁻¹), low (<380 AU ml⁻¹) and high (>380 AU ml⁻¹) anti-SARS-CoV-2 spike RBD total Ig responses. Statistical comparisons of the proportion of low and no versus high response and no versus low and high response in disease groups compared to healthy controls are presented. b, Magnitude of serological response in disease groups and healthy controls. Statistical comparisons comparing disease group to healthy controls are presented. c, Anti-SARS-CoV-2 spike RBD total Ig responses comparing previously infected with infection-naive patents. Statistical comparison of infection-naive individuals and previously infected individuals within each group is presented. d, Anti-SARS-CoV-2 spike RBD total Ig responses separated by vaccine type. Statistical comparison of vaccine type in each disease group is presented. Unpaired statistical comparison was made on all groups using a two-sided Kruskal–Wallis with post hoc Dunn’s testing. Comparisons of proportions were performed using χ² or Fisher’s exact tests adjusted for significance using Bonferroni correction (adjusted alpha = 0.003). Only significant comparisons are presented. * indicates statistically significant by Bonferroni-adjusted alpha. Boxes represent median and IQR; whiskers represent ±1.5× IQR. AAV, ANCA-associated vasculitis; CD, Crohn’s disease; HC, healthy controls; HD, hemodialysis; HD on IS, hemodialysis on immunosuppression; HM, hemotological malignancy; IA, inflammatory arthritis; L-AI, autoimmune hepatitis; L-Cir, liver cirrhosis; L-Tr, liver transplant; SC, solid cancer; UC, ulcerative colitis.